Bio-Techne Corp
XBER:TE1

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
XBER:TE1
Watchlist
Price: 49.8 EUR
Market Cap: €11.8B

Wall St Price Targets

TE1 Price Targets Summary
Bio-Techne Corp

Wall Street analysts forecast TE1 stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TE1 is 46.03 EUR with a low forecast of 34.86 EUR and a high forecast of 58.43 EUR.

Lowest Forecast
Price Target
34.86 EUR
30% Downside
Average Forecast
Price Target
46.03 EUR
8% Downside
Highest Forecast
Price Target
58.43 EUR
17% Upside
Bio-Techne Corp Competitors:
Price Targets
BARK
Bark Inc
152% Upside
BWXT
BWX Technologies Inc
18% Upside
AAT
American Assets Trust Inc
-15% Downside

Revenue
Forecast

11% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
11% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 4 years is 5%.

Gross Profit
Forecast

10% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
10% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 4 years is 7%.

Operating Income
Forecast

3% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-30%
Average Miss
3% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-30%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 4 years is 18%.

Pre-Tax Income
Forecast

-4% / Year
Past Growth
68% / Year
Estimated Growth
Estimates Accuracy
-38%
Average Miss
-4% / Year
Past Growth
68% / Year
Estimated Growth
Estimates Accuracy
-38%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -4%. The projected CAGR for the next 3 years is 68%.

Net Income
Forecast

-3% / Year
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
-30%
Average Miss
-3% / Year
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
-30%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been -3%. The projected CAGR for the next 4 years is 53%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is TE1's stock price target?
Price Target
46.03 EUR

According to Wall Street analysts, the average 1-year price target for TE1 is 46.03 EUR with a low forecast of 34.86 EUR and a high forecast of 58.43 EUR.

What is the Revenue forecast for Bio-Techne Corp?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 4 years is 5%.

What is the Gross Profit forecast for Bio-Techne Corp?
Projected CAGR
7%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 4 years is 7%.

What is the Operating Income forecast for Bio-Techne Corp?
Projected CAGR
18%

Over the last 13 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 4 years is 18%.

What is the Pre-Tax Income forecast for Bio-Techne Corp?
Projected CAGR
68%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -4%. The projected CAGR for the next 3 years is 68%.

What is the Net Income forecast for Bio-Techne Corp?
Projected CAGR
53%

Over the last 13 years, the compound annual growth rate for Net Income has been -3%. The projected CAGR for the next 4 years is 53%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett